Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer

Sacituzumab govitecan was initially approved in April 2020 under accelerated approval for the treatment of patients with metastatic triplenegative breast cancer who received at least two prior therapies for metastatic disease. A confirmatory phase III trial evaluating sacituzumab govitecan vs. chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleming, Patrick J., Karpio, Sylvia, Lombardo, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2021
Materias:
Prescriber's Corner
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504932/
https://www.ncbi.nlm.nih.gov/pubmed/34671504
http://dx.doi.org/10.6004/jadpro.2021.12.7.8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504932/
https://www.ncbi.nlm.nih.gov/pubmed/34671504
http://dx.doi.org/10.6004/jadpro.2021.12.7.8

Ejemplares similares